Introduction
Myxomatous mitral valve disease (MMVD) is the most common acquired cardiac disease of the dog and is a major cause of morbidity and mortality in this species (Darke, 1987; Beardow and Buchanan, 1993; Hamlin et al., 1996; Haggstrom et al., 2004) . Much is known about the diagnosis and treatment of MMVD, but only recently has attention focussed on better understanding of the pathobiology of this disease. Recent research builds on original pathological studies from more than 30 years ago, and with available molecular tools an exciting era of research in canine MMVD is now underway. While there are similarities with human MMVD, there are also clear differences in morphological, genetic and protein expression parameters, and extrapolating between species must be done with caution (Hulin et al., 2013; Roberts et al., 2014; Thalji et al., 2015) . For example, in human MMVD a large component of the pathology is fibrosis, while in canine MMVD, accumulation of a myxomatous substance within the core of the valve is the main change (McDonald et al., 2002b; Roberts et al., 2014) 
Valve Structure
The mitral valve consists of two leaflets, anterior (septal) and posterior (mitral) and is connected to the heart by the annulus fibrosus and to the papillary muscles by the chordae tendineae (Fig. 1) . The chordae attach either to the valve edge (first order) or to the ventricular surface close to the valve edge (second order). The latter insertions give a rough and irregular surface to the underside of the leaflets, while the atrial surface is smooth. There can be marked variation in chordae/papillary muscle organization, and such variation is regarded as normal. Overall the normal leaflet has a partially translucent appearance and is roughly divided into proximal, mid and distal zones, the latter also known as the 'free edge'.
Microscopically, each leaflet has an atrial and ventricular surface and a single layer of endothelial cells, continuous with that lining the atrium and ventricle, covers each surface ( Fig. 2) . In the mid-zone there are three identifiable layers, the atrialis, spongiosa and fibrosa, each containing varying amounts of collagen I, III, IV and VI, laminin, fibronectin and heparan sulphate (Aupperle et al., 2009a) . The thin atrialis is also rich in elastin with a mixed amount of scattered collagen fibres and valvular interstitial cells (VICs). The spongiosa consists of loose collagen fibres, scattered collagen bundles and small numbers of thin elastin fibres embedded in glycosaminoglycan (GAG)-rich ground substance with scattered VICs. Immediately beneath the spongiosa is the dense, well-organized fibrosa layer with well-defined collagen bundles and scattered VICs. The fibrosa is continuous with the annulus fibrosus and branches off to form the core of the chordae tendineae. The thin subendothelial layer on the ventricular side has collagen fibres and occasional elastin, and is suggested to be an additional fourth layer (ventricularis) similar to that seen in the aortic valve (Buchanan, 1977; Anderson and Wilcox, 1996; Fox, 2012) . Towards the distal zone (free edge) the distinction between spongiosa and fibrosa, at least in some dogs, can become indistinct and the valve at this level appears to almost entirely consist of spongiosa covered by endothelium (Han et al., 2013b) . Cardiac muscle extends from the atrial myocardium for a variable length along the valve leaflets, and while this lessens with age, likely has important functional implications in valve mechanics (Culshaw et al., 2010; Fox, 2012) .
Gross Pathology
Gross changes to the leaflets in MMVD are often described according to the Whitney classification ( Fig. 3) , and are graded 0 to 4 with 0 being normal and 4 the most advanced form of the disease (Pensinger, 1965; Pomerance and Whitney, 1970; Whitney, 1974; Han et al., 2010) . These grades have a close association with advancing age and the intensity of cardiac murmur (Han et al., 2010) . Typically, the disease starts with small numbers of discrete nodules developing on the free edge of the leaflet with intervening areas of translucent leaflet (grade 1), progressing to the development of larger nodules (grade 2), coalescence of these nodules (grade 3), involvement of the chordae, and finally, gross distortion and ballooning of the leaflets with marked chordal thickening and eventual chordal rupture (grade 4). The main difficulty with grading can be in distinguishing between normal and grade 1, and an alternative approach is to use measurement of free-edge thickness as an index of severity, but this has not been adopted widely (Disatian et al., 2008 (Disatian et al., , 2010 .
Change in the thickness of the edge of the valve, associated with disease progression, has also been confirmed on histological samples, with the posterior leaflet being slightly thicker than the anterior (Han et al., 2010) . Additionally, there is lengthening of the valve with advancing disease as evidenced by alteration in the ratio of the anterior-to-posterior 5 leaflet length, but the anterior leaflet is always longer than the posterior leaflet, irrespective of disease severity (Han et al., 2010) . Chordal changes mirror those seen with the valve proper with swelling, thickening and eventual rupture, but chordal changes have not been investigated in detail (Fox, 2012) .
Microscopical Changes
On histopathology the most striking changes are expansion of the spongiosa and loss or destruction of the fibrosa (Fenoglio and Tuan duc, 1972; Pomerance and Whitney, 1970; Whitney, 1974; Buchanan, 1977; Kogure, 1980; Hadian et al., 2007; Han et al., 2010) (Fig. 4 ). The myxomatous changes involve expansion of the loose connective tissue of the spongiosa and an increase in amorphous metachromatically-stained mucoid material (myxomatous degeneration) (Pensinger, 1965; Pomerance and Whitney, 1970; Buchanan, 1977; Han et al., 2010) . Amyloid deposition has been reported in a small number of dogs with MMVD (Schneider et al., 1971) . The remnants of the fibrosa can be appreciated even in advanced disease, but this layer is markedly disorganized (Han et al., 2013b) . Previously, these changes had been described as fibro-elastic proliferation, but this does not appear to be the case and it is connective tissue disorganization that is the main change (Pensinger, 1965; Whitney, 1967; Buchanan, 1977; Aupperle et al., 2009c; Hadian et al., 2009) . Overall, depending on the grade of disease, there are changes in laminin, elastin and collagens IV and VI in the subendothelium, and elastin, fibronectin and collagens I and II deeper in the leaflet (Aupperle et al., 2009c) . In the myxomatous areas there is a measurable reduction in connective tissue density and increase in GAG content and this reduction equates with disease severity (Han et al., 2010) . An accumulation of fat cells adjacent to the fibrosa and mainly towards the valve base has been reported, but may in part be age related (Pomerance and Whitney, 1970) . 6 Qualitative and quantitative differences in total collagen/connective tissue content have been established (Corcoran et al., 2004; Hadian et al., 2007 Hadian et al., , 2010 Han et al., 2013a) .
There is a reduction in collagen content in lesion areas and these areas tend to be patchy and only coalesce into more contiguous areas as the disease progresses (Hadian et al., 2007) .
Changes are typically close to the valve edge and difficult to identify towards the mid and basal zone, but image analysis of cell macerated (i.e. valves decellularized with sodium hydroxide) scanning electron microscopy images has identified mild changes in the mid-zone (Han et al., 2013b) . Overall, there is distinct alteration in collagen bundle orientation and fibril alignment in diseased areas (Black et al., 2005; Hadian et al., 2007; Han et al., 2013b) .
There is a reduction in total tissue content (i.e. collagenous and non-collagenous) in myxomatous areas and increased expression of GAGs (Hadian et al., 2007; Han et al., 2010) .
Nevertheless, at least in mild to moderate disease, there is a 20% decrease in collagen fibril numbers, but only a 10% decrease in total collagen content (Hadian et al., 2010) .
Coupled with these change in collagen there is an increase in immature reducible covalent cross-linkage bonds in collagen in affected areas and a reduction in irreducible mature cross-linkages (Hadian et al., 2010) . This implies that there is failure to produce mature fibrillar collagen to replace normal collagen turnover, and improper collagen assembly which can be appreciated at the ultrastructural level (Corcoran et al., 2004; Black et al., 2005; Han et al., 2013b) . The production of irreducible (mature) cross-linkages requires lysyl-oxidase, which is known to become depleted in old age, and therefore, changes are also seen as part of the normal ageing process (Eyre et al., 1988; McDonald et al., 2002a, b) .
However, these changes are seen in young dogs and the increased deposition of proteoglycans, which is known to occur with MMVD, may interfere with cross-linkages in collagen. The likely involvement of activated myofibroblasts (VICs) in this process, in both 7 the human and canine forms of the disease, is of major interest (Rabkin et al., 2001; Black et al., 2005; Disatian et al., 2008; Han et al., 2008) . Similar changes are noted in the chordae and include significant reduction in collagen, increase in GAG content and altered GAG composition (Buchanan, 1977; Baker et al., 1988) . Fat cell accumulation has been reported in the chordae of affected dogs, and is an interesting observation as a change in fat content is also reported for the valve base (Ernst et al., 1973b; Buchanan, 1977; Culshaw et al., 2010) .
All of these changes are likely to contribute to the mechanical instability of the entire mitral valve complex, and have catastrophic consequences if the chordae rupture.
Cellular Changes

Interstitial and Stromal Cells
Cellular changes are noted in diseased canine and human valves (Ernst et al., 1973b; Soini et al., 2001; Rabkin-Aikawa et al., 2004; Disatian et al., 2008; Han et al., 2008 Han et al., , 2013a (Fig.   5a ). There is an overall decrease in cell numbers in overtly myxomatous zones in the centre of the leaflet with a significant increase in cell numbers in the peripheral subendothelial zone and close to areas of endothelial cell loss (Han et al., 2010 (Han et al., , 2013a . Cell shape does not change with advancing disease and the interstitial cells maintain a spindle shape (Han et al., 2010) . More importantly, there is phenotypic alteration of the valvular interstitial cells from a presumed quiescent vimentin-positive fibroblast-like cell to a more activated α-smooth muscle actin (α-SMA)-positive cell type (i.e. activated myofibroblasts) (Black et al., 2005; Disatian et al., 2008; Han et al., 2008) . The α-SMA-positive cells increase in number and are located primarily close to the endothelium, with a partial preference for the atrialis layer (Disatian et al., 2008; Han et al., 2008 Han et al., , 2013a . Increased expression of Ki-67 suggests there is cellular proliferation, but what contribution cell migration might make to this is unknown (Lu et al., 2016) . The contribution from the endothelium via endothelial-to-mesenchymal transition (EMT) should also be considered, and EMT and recapitulation developmental pathways have been partially identified in MMVD (Lu et al., 2015a (Lu et al., , 2016 . Throughout the diseased valve stroma many cells express embryonic smooth muscle myosin (Smemb), another putative marker of myofibroblast activation, while some co-express α-SMA and Smemb suggestive of heightened differentiation capacity (Disatian et al., 2008; Lu et al., 2016) .
VICs can be found in all layers of the valve and may be divided into five identifiable phenotypes: (1) embryonic progenitor endothelial/mesenchymal cells, (2) quiescent VICs (qVICs), (3) activated VICs (aVICs), (4) progenitor VICs (pVICs), and (5) osteoblastic VICs (obVICs) . During the earliest stage of valve development, endothelial cells invade the endocardial cushion and are transformed into embryonic progenitor endothelial/mesenchymal cells, and the cushion undergoes matrix remodelling (Armstrong and Bischoff, 2004) . Transforming growth factor (TGF)-β, bone morphogenetic proteins, Notch signalling, vascular endothelial growth factor and hyaluronic acid contribute to the regulation of this EMT (Choy et al., 1990; Armstrong and Bischoff, 2004; Noseda et al., 2004; Lu et al., 2015b) . Once the valve is formed, qVICs predominate and are thought to maintain valve structure and function and inhibit angiogenesis in the leaflets (i.e. normal lifelong valve remodelling). The qVICs are then presumed to become activated to aVICs in response to disease and injury, and then regulate the pathobiological responses of the valve . Small numbers of desmin-positive VICs with chondroblast morphology (obVICs) can be seen in some diseased valves, but calcification is not a clearly identified feature of mitral valve disease in the dog (Han et al., 2008) . However, α-SMApositive cells can be located in the proximal and mid zones of normal and mildly-affected valves, but only begin to appear in large number in the distal zone as disease develops (Lu, personal communication) . In diseased valves, a re-emergence of EMT has been identified, 9 with changes in expression of a range of genes associated with valve development and EMT. This is best exemplified by emerging co-expression of hyaluronic acid synthase (HAS)-2 and α-SMA in endothelial cells, and in the stroma, reduced CDH5 gene expression and increased expression of HAS-2 with stromal deposition of hyaluronic acid (Lu et al., 2015a) . Similar differentiation capacity has been identified in ovine mitral and porcine aortic valve endothelial cells Wylie-Sears et al., 2011; Mahler et al., 2013) .
Furthermore, in diseased valves a population of von Willebrand factor (vWF)-positive cells can be identified in the stroma, which might be endothelial in origin (Lu et al., 2016) .
Irrespective of their origin or lineage, aVICs are found to lie in areas of loose collagen bundles and can be seen to exude fibrillar collagen on electron microscopy, with many localized away from the central myxomatous areas and close to the valve edge (Ernst et al., 1973a (Ernst et al., , 1974a Black et al., 2005) . This change in cell phenotype and localization coincides with disease progression with demonstrable temporal and spatial alteration in valve cellularity (Disatian et al., 2008; Han et al., 2008; Lu et al., 2016) . However, the increased numbers of Smemb-positive cells in the spongiosa, and to a lesser extent the fibrosa, suggests distribution of activated myofibroblasts throughout the entire depth of the valve (Disatian et al., 2008) . The relative contributions of these two activated myofibroblast subpopulations to the overall disease process are unknown. What is interesting is that the Smemb-positive cells show much greater expression of 5-hydroxytryptamine (HT) compared with α-SMA-positive cells, considering the putative role of 5-HT/TGF-β signalling in disease pathogenesis (Disatian et al., 2008) . In the more advanced stages of the disease, interstitial cells can appear more like smooth muscle, form syncytia and anchor to collagen bundles, and this has been suggested to compensate for the reduction in valve tensile strength (Ernst et al., 1974b; Black et al., 2005) . Coupled with this regionalization of stromal cells, there is a reduction in cell number in overtly myxomatous areas compared with normal spongiosa, but no further change in cell number as the disease progresses (Ernst et al., 1973a; Han et al., 2008) .
However, in both human and canine mitral valve disease, there is an increase in total cell number through the entire depth of the valve (Rabkin et al., 2001; Rabkin-Aikawa et al., 2004; Disatian et al., 2008) . A confounding factor in interpreting changes in cell number is the increased thickness of diseased valves compared with normal, and when cell numbers are indexed to area there is a decrease in cell density (Han et al., 2010) . It is clear that there is congregation of cells towards the periphery, close to the overlying endothelium and in areas of endothelial loss (Disatian et al., 2008; Han et al., 2008 Han et al., , 2013a . Experimental ovine valve injury models show the same effect (Lester et al., 1992 (Lester et al., , 1993 Black et al., 2005; Han et al., 2010) .
The exact identity of all of the cells present in myxomatous areas is not known as some are both vimentin and α-SMA negative. However, in diseased valves the majority of the cells throughout the valve are Smemb positive and this, coupled with α-SMA expression in some cells and their spindle shape, indicates that they mostly have an interstitial phenotype (Disatian et al., 2008; Han et al.2008) . In human MMVD, some cells are CD34 and CD117 positive, suggesting a circulating fibrocyte, mast cell and/or stem cell lineage, but further work is needed to determine their precise phenotypes and to see if the same populations occur in dogs (Barth et al., 2004 (Barth et al., , 2005 . In dogs with advanced disease there is evidence of a marginal increase in the number of mast cells in affected valves (Han et al., 2008) . However, in dogs with severe MMVD there is no evidence of involvement of the resident macrophage population in disease pathogenesis, or recruitment of inflammatory cells, as evidenced by the lack of expression of CD68, CD11c, CD45 and MAC387, despite increased expression of gene transcripts encoding for several inflammatory cytokines and adhesion molecules (Disatian et al., 2008; Han et al., 2008; Disatian and Orton, 2009; Lu et al., 2016) . Electron microscopy has also failed to identify inflammatory cells in the stroma of diseased canine valves (Ernst et al., 1974b; Black et al., 2005) .
Valvular Endothelial Cells
Changes to the endothelium are clearly seen in MMVD. Scanning electron microscopy demonstrates areas of endothelial loss, cellular pleomorphism and increased numbers of surface micro-appendages (Ernst et al., 1973a (Ernst et al., , 1974b Corcoran et al., 2004) (Fig. 5b) . These changes are suggestive of basement membrane abnormalities, endothelial cell death and reactive changes in the endothelium in response to insult. Similar changes can be identified on transmission electron microscopy, with interstitial cell accumulation in the immediate subendothelium and disruption of the basement membrane (Black et al., 2005; Han et al., 2013a) . Endothelial damage has also been detected using expression of the endothelial cell markers CD31 and vWF, with clear reduction of expression of these markers in canine MMVD, and further reduction as disease progresses (Disatian et al., 2008; Lu et al., 2016) .
The transition of VECs as part of EMT is also an important change (Lu et al., 2015a) .
It has been hypothesized for many years that repeated damage to the leaflet edge is likely to play a role in the aetiopathogenesis of canine MMVD and the localization of lesions to the valve edge with demonstrable changes to the endothelium would support that assertion.
Functional changes in canine valve endothelium have been identified, with increased nitric oxide (NO) synthase activity (i.e. expression of NADH, NADPH reductase and diaphorase), increased endothelin (ET) receptor expression (associated with severity), subendothelial collagen degeneration and deposition of mucopolysaccharides (Ernst et al., 1973b; Mow and Pedersen, 1999; Olsen et al., 2003) . This suggests that NO and ET might contribute to the development of MMVD, as both have an effect on extracellular matrix production (Olsen et al., 2003) . The migration and localization of activated myofibroblasts towards the endothelium in MMVD may be a part of this process and would fit into the endothelial injury model of disease pathogenesis (Black et al., 2005; Disatian et al., 2008; Han et al., 2008) .
Molecular and Biochemical Changes
Activation of VICs has been shown to be associated with increased extracellular matrix (ECM) secretion (Durbin and Gotlieb, 2002) . Several lines of evidence have shown that phenotypic alteration in VICs is crucial to the development of myxomatous degeneration and probably accounts for the derangement of the valvular ECM seen in both canine MMVD and human mitral valve disease (Rabkin et al., 2001; Rabkin-Aikawa et al., 2004; Black et al., 2005; Disatian et al., 2008; Han et al., 2008) . The ECM derangement may in part be due to altered expression of matrix metalloproteinases (MMPs), tissue inhibitors of MMPs (TIMPs), the 'A disintegrin and metalloproteinase with thrombospondin motifs' (ADAMTS) family of metalloproteases and cathepsins (Soini et al., 2001; Rabkin-Aikawa et al., 2004; Aupperle et al., 2009a Aupperle et al., , 2010 Lu et al., 2015c) . In the dog, with advancing valvular disease, there is decreased expression of the gelatinase MMP-2, an increase in cell surface-bound MMP-14 and an increase in TIMP-2 and TIMP-3 expression, illustrating a change in the balance of catabolic enzymes and their inhibitors that are important in normal valve remodelling (Aupperle et al., 2009b) . Changes in gene expression for the MMPs and TIMPs in both human and canine MMVD do not always match that seen on immunohistochemistry, but a 4.5-fold increase in TIMP-1 has been reported (Oyama and Chittur, 2006; Lu et al., 2015c; Greenhouse et al., 2016) . MMP-14 is important in the degradation of collagens I, II and III and its presence in the valves of dogs with MMVD, but not in human diseased valves, probably reflects a dog-specific alteration in VIC phenotype (Soini et al., 2001; Aupperle et al., 2009b) . Mice with cardiac-specific transgenic expression of active MMP-2 have been 13 shown to develop marked mitral valve thickening and prolapse with a major loss of collagen bundles and a large accumulation of acidic GAGs, similar to the pathological changes observed in canine MMVD (Aupperle et al., 2009b; Mahimkar et al., 2008) . MMP substrates can also include basement membrane components, and basement membrane loss is seen on transmission electron microscopy of diseased dog valves (Matrisian, 1990; Black et al., 2005; Han et al., 2013a) .
Gene and protein expression changes implicated in basement membrane disarray have been reported, including alterations in expression of genes encoding NID1, LAM1, LAMA2, CTSS COL6A3, and the proteins laminin, collagen IV and fibronectin (Aupperle et al., 2009a; Lu et al., 2015c) . The cathepsin-encoding genes CTSK and CTSS are significantly upregulated in diseased valves and in human MMVD aVICs (Rabkin et al., 2001; Lu et al., 2015c) . Expression of these genes is induced by a range of inflammatory cytokines, including interleukins and tumour necrosis factor (TNF)-α, and the substrates of these molecules include elastin, collagens, fibronectin, laminin and nidrogen. While tissue protein expression of the ADAMTS peptidases has not been reported, there are interesting gene changes found in both human and canine MMVD (Lu et al., 2015c; Thalji et al., 2015) . There is significant down-regulation of ADAMTS2, ADAMTS9, ADAMTS19 and ADAMTSL4 in diseased canine valves (Lu et al., 2015c) . Additionally, a strain of mice with knockout of the gene encoding the proteoglycan cleaving protein ADAMTS5 has been shown to develop a MMVD phenotype due to a lack of proteoglycan clearance. Considering their function in pro-collagen maturation, deposition of the small leucine rich proteoglycan (SLRP) versican and regulation of fibrillin-1 and elastin production (Marfan syndrome) respectively, these changes in ADAMTS gene expression fit in with the known valve pathology. Of all of the catabolic enzymes that might be contributing to the pathology of MMVD, it is study of molecules of the ADAMS family and the cathepsins, but not necessarily the MMPs, which might be most informative (Lu et al., 2015c; Greenhouse et al., 2016) .
Alteration in proteoglycan (PG) and GAG expression is also a cardinal feature of mitral valve disease, but has been reported to a limited extent in the dog (Ernst et al., 1973b; Han et al., 2010) . Increased PG content in canine valves has been extrapolated indirectly by using cell maceration scanning electron microscopy (Han et al., 2013b) . Reduction in fibrillar connective tissue components in human myxomatous mitral valve disease coincides with increased expression of GAGs (Cole et al., 1984; Lis et al., 1987; Whittaker et al., 1987; Tamura et al., 1995; Grande-Allen et al., 2003) . However, the relative proportions of the different GAGs also changes with age in normal human subjects, and this is a confounding factor when considering disease-associated changes in a disease that is age-dependent (Murata, 1981; McDonald et al., 2002b) . PGs and GAGs are necessary for the proper assembly of the ECM, interact with other important structural proteins such as fibronectin and laminin and have a role in elastin fibrogenesis (Fornieri et al., 1987) . Hyaluronic acid is the most abundant GAG in mitral valves, but other proteoglycans, particularly the SLRPs, are likely to have an equally important role in maintaining a healthy ECM (Radermecker et al., 2003) . SLRP gene transcripts have the highest signal intensity of all transcripts in normal and diseased canine valves and there is significantly decreased expression of CHAD and KERA (encoding keratocan) in the canine valve (Lu et al., 2015c) . Keratocan is of particular interest as it is important in collagen assembly. Decorin and biglycan are increased in the diseased canine valvular proteome and biglycan, decorin and versican are increased in human MMVD valve tissue (Gupta et al., 2008; Lacerda et al., 2009; Radermecker et al., 2003) .
Decorin plays a critical role in collagen fibrillogenesis, while biglycan is found in both collagen-and elastin-rich regions and also influences elastic fibre formation (Reinboth et al., 15 2002; Gupta et al., 2008) . The accumulation of GAGs in MMVD is a major contributor to valve thickening and contributes to the mechanical failure of the valve (Tamura et al., 1995) .
Elastin is particularly interesting as it has greater tensile strength than collagen and may contribute disproportionately to valve mechanical integrity and strength (Tamura et al., 1995) . An increase in elastic fibres has been reported in human and canine myxomatous mitral valves, but the fibres are thinner than normal, arranged into more distinct bundles, and the bundles are more widely separated than in normal leaflets (Tamura et al., 1995) .
The signalling pathways that drive all of these structural changes are complex and only understood partially. Global valve tissue transcriptomic profiling has identified a wide range of gene changes associated with MMVD in man and dogs (Oyama and Chittur, 2006; Hulin et al., 2012; Sainger et al., 2012; Lu et al., 2015c; Thalji et al., 2015; Greenhouse et al., 2016) . In human MMVD, further major gene changes include the expression of genes involved in control of oxidative stress (an endothelium function) and downregulation of the endothelin receptor type A (ET-A) gene EDNRA (Hulin et al., 2012) . In the dog there is upregulation of the gene encoding the 5-HT2B receptor, but this is not seen in human MMVD. In contrast, there is greater evidence of activation of TGF-β signaling pathways in human MMVD that will drive fibrosis (Hulin et al., 2012; Sainger et al., 2012; Thalji et al., 2015; Greenhouse et al., 2016) . Changes in TGF-β protein and gene expression have been identified in canine MMVD using immunohistochemistry and reverse transcriptase polymerase chain reaction for TGF-β1, -2 and -3 and TGF-β2, but transcriptomic profiling has not found such changes (Oyama and Chittur, 2006; Aupperle et al., 2008; Obayashi et al., 2011; Moesgaard et al., 2014; Lu et al., 2015c) . Furthermore, upregulation of members of the transcription factor family NFATc is found in human MMVD, but is downregulated in the canine transcriptome (Lu et al., 2015c; Greenhouse et al., 2016) . NFATc has an important function in the production of ECM. These canine/human differences are not unexpected considering that fibrosis is not a cardinal feature of canine MMVD (Buchanan, 1977; Roberts et al., 2014) .
Up-regulation of the 5-HT2B receptor in the dog is an interesting finding as it is reminiscent of the pathological change in the valve that occurs with use of the appetite suppressant phentermine-fenfluramine and various anti-Parkinsonian drugs (Connolly et al., 2009 ). The 5-HT/TGF-β signalling pathway is important in ECM production, including collagen and fibronectin, but 5HT has not been shown to transform VICs into α-SMApositive cells, a cardinal feature of MMVD (Connolly et al., 2009; Oyama and Levy, 2010) .
The increased protein expression of the 5-HT2B receptor, the rate limiting enzyme in serotonin synthesis tryptophan hydroxylase-1 (primarily in Smemb-positive cells), phosphorylated ERK-1 and TGFβ-1 receptors in canine MMVD would support a possible role for enhanced serotonin signalling in MMVD (Arndt et al., 2009; Disatian and Orton, 2009 ). However, the downregulation of proteins important for tryptophan hydroxylase function may mean that this potential mechanism of disease pathogenesis might not be activated, and the exact role of 5HT in the pathogenesis of MMVD is unclear (Lacerda et al., 2009 ).
In the dog, cluster analysis of all gene changes suggests that the most affected biologically relevant functions are inflammatory response, cellular movement, cardiovascular development, extracellular matrix organization and epithelial-to-mesenchymal transition, as well as the endothelial function pathways, caveolar-mediated endocytosis signalling, endothelin-1 signalling and epithelial adherens junctions remodelling (Oyama and Chittur, 2006; Lu et al., 2015c) . Caveolar-mediated endocytosis regulates endothelial cell growth, endocytosis and cell migration and reduces TGF-β-induced fibroblast activation (Del Galdo et al., 2008; Sowa, 2012) . In canine and human MMVD there is increased expression of genes encoding inflammatory molecules such as vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1, selectin E (SELE), Toll-like receptor (TLR)-4, TLR-8, interleukin (IL)-18 and IL-6, which can trigger ECM changes and EMT (Oyama and Chittur, 2006; Hulin et al., 2012; Sainger et al., 2012; Mahler et al., 2013; Lu et al., 2015c) .
Activation of low density lipoprotein receptor (LDLR) has been reported in valves affected by MMVD, where this molecule is predicted to upregulate expression of a variety of inflammatory mediators (Olsen et al., 1999; Lu et al., 2015c ). An experimental mechanical endothelial shear stress model has been shown to generate reactive oxygen species that act as intracellular secondary messengers and result in elevation of inflammatory cytokines, particularly ICAM-1 (Chiu et al., 1997) . The increase in expression of genes encoding IL-6, IL-1 and IL-10, as well as the adhesion molecules VCAM-1 and ICAM-1, may represent a response to the endothelial damage associated with MMVD (Corcoran et al., 2004; Han et al., 2013a) . Upregulation of genes associated with oxidative stress has been identified in canine and human MMVD and the increase in inflammation-associated cytokines might be in response to reactive oxygen species (ROS) generated by endothelial shear stress (Hulin et al., 2012; Sainger et al., 2012; Lu et al., 2015c) . All of these gene functions are not unexpected considering what is known about valve pathology. Groups of gene changes, which on first examination might not appear to have related functions, clearly contribute to valve pathology by affecting VEC function, transition and loss, VIC activation, proliferation and migration, catabolism of the ECM and aberrant remodelling of the same, without inducing a fibrotic response in the dog. A similar array of changes, but with subtle differences, illustrate the role of fibrosis in human MMVD and the contrast with the canine disease.
Conclusion
There have been major advances in understanding of the pathobiology of canine MMVD in the last 10 years and research activities are ongoing and expanding at various centres. In addition, there is a large amount of comparative data emerging from studies of human MMVD and associated diseases, but caution must be exercised in extrapolating new findings between man and the dog. The availability of dog-specific molecular tools has allowed the linking of pathological events to effects at the levels of gene and protein expression.
However, since the pathological data are more than 30 years old, there is also a need to reappraise the morphological changes seen with MMVD at the gross, histological and ultrastructural levels. An observation of the same problems in human MMVD research has recently been reported showing that fundamental aspects of valve pathology, particularly the fibrotic response, have been over-looked (Roberts et al., 2014) . 
